JP2014503475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503475A5 JP2014503475A5 JP2013535421A JP2013535421A JP2014503475A5 JP 2014503475 A5 JP2014503475 A5 JP 2014503475A5 JP 2013535421 A JP2013535421 A JP 2013535421A JP 2013535421 A JP2013535421 A JP 2013535421A JP 2014503475 A5 JP2014503475 A5 JP 2014503475A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- disease
- liposome
- terminus
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 41
- 239000002502 liposome Substances 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 8
- 230000002776 aggregation Effects 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 8
- 230000007815 allergy Effects 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- -1 diglycerides Chemical class 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 239000000232 Lipid Bilayer Substances 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 108091005601 modified peptides Proteins 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000012474 protein marker Substances 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 11
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- LJUIOEFZFQRWJG-GHYFRYPYSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O LJUIOEFZFQRWJG-GHYFRYPYSA-N 0.000 description 2
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000021550 spleen neoplasm Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188832.9 | 2010-10-26 | ||
| EP10188832 | 2010-10-26 | ||
| PCT/EP2011/068797 WO2012055933A1 (en) | 2010-10-26 | 2011-10-26 | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503475A JP2014503475A (ja) | 2014-02-13 |
| JP2014503475A5 true JP2014503475A5 (enExample) | 2014-10-16 |
| JP6027011B2 JP6027011B2 (ja) | 2016-11-16 |
Family
ID=44872345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535421A Active JP6027011B2 (ja) | 2010-10-26 | 2011-10-26 | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9687447B2 (enExample) |
| EP (1) | EP2632434B1 (enExample) |
| JP (1) | JP6027011B2 (enExample) |
| KR (1) | KR101854943B1 (enExample) |
| CN (1) | CN103189050B (enExample) |
| AR (1) | AR083561A1 (enExample) |
| AU (1) | AU2011322553B2 (enExample) |
| CA (1) | CA2813833C (enExample) |
| TW (1) | TW201223561A (enExample) |
| WO (1) | WO2012055933A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140314837A1 (en) * | 2011-09-23 | 2014-10-23 | Ac Immune S. A. | Vaccine Therapy |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| CN103601796B (zh) * | 2013-11-11 | 2016-09-21 | 杭州璞题生物科技有限公司 | 亨廷顿蛋白的棕榈化修饰方法 |
| MX389323B (es) | 2013-12-03 | 2025-03-20 | Univ Northwestern | Particulas liposomales, metodos para elaborarlas y sus usos. |
| WO2015163424A1 (ja) | 2014-04-23 | 2015-10-29 | 株式会社ニチレイバイオサイエンス | 標的マーカー検出用組合せ物 |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗ｔｎｆ化合物 |
| WO2017136467A1 (en) * | 2016-02-01 | 2017-08-10 | Exicure, Inc. | Surface functionaliztion of liposomes and liposomal spherical nucleic acids (snas) |
| KR102617833B1 (ko) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
| KR102710762B1 (ko) | 2017-10-25 | 2024-09-25 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| WO2019134981A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| US10828351B2 (en) * | 2018-04-10 | 2020-11-10 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
| CN112512508A (zh) * | 2018-07-24 | 2021-03-16 | 台湾微脂体股份有限公司 | 含有治疗失智症的治疗剂的缓释药物组合物及其用途 |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| KR20210125048A (ko) | 2019-02-08 | 2021-10-15 | 에이씨 이뮨 에스.에이. | 인산화 타우 펩티드 백신의 안전한 투여 방법 |
| WO2020212593A1 (en) | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| CN114173812A (zh) | 2019-04-24 | 2022-03-11 | 杨森制药公司 | Tau疫苗的异源给予 |
| CN113853214A (zh) | 2019-05-21 | 2021-12-28 | Ac免疫有限公司 | 抗Aβ疫苗治疗 |
| CA3137882A1 (en) | 2019-05-23 | 2020-11-26 | Tamara SEREDENINA | Anti-tdp-43 binding molecules and uses thereof |
| WO2021048324A1 (en) | 2019-09-10 | 2021-03-18 | Ac Immune Sa | Novel molecules for diagnosis |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| JP2023504699A (ja) | 2019-12-04 | 2023-02-06 | エイシー イミューン ソシエテ アノニム | 治療および診断のための新規な分子 |
| US11913964B2 (en) * | 2020-02-27 | 2024-02-27 | Adeptrix Corp. | Multiplexed bead-based analytical assays |
| WO2022003443A1 (ko) * | 2020-06-30 | 2022-01-06 | 아이진 주식회사 | 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물 |
| JP2023537761A (ja) | 2020-08-14 | 2023-09-05 | エイシー イミューン ソシエテ アノニム | ヒト化抗ｔｄｐ－４３結合分子およびその使用 |
| WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| CR20240378A (es) | 2022-02-16 | 2024-10-03 | Ac Immune Sa | Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas |
| WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
| WO2024156908A1 (en) | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Liposomal construct |
| EP4654990A1 (en) | 2023-01-26 | 2025-12-03 | AC Immune SA | Anti-abeta vaccine therapy |
| CN120917043A (zh) | 2023-03-08 | 2025-11-07 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| WO2025196262A1 (en) | 2024-03-22 | 2025-09-25 | Ac Immune Sa | Immunoassay involving antibodies binding vaccine adjuvants |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565696A (en) | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| EP0203676B1 (en) * | 1985-04-19 | 1992-01-29 | The Wistar Institute Of Anatomy And Biology | Vaccine for generating an immunogenic t cell response protective against a virus |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| IT1257893B (it) | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| WO1994010198A1 (en) | 1992-11-02 | 1994-05-11 | Yves Claude Nicolau | Method of reducing multidrug resistance in cells and tissues |
| US20040248799A1 (en) | 1993-05-27 | 2004-12-09 | Holaday John W. | Compositions and methods for treating cancer and hyperproliferative disorders |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| JP3759759B2 (ja) | 1994-03-04 | 2006-03-29 | 日本油脂株式会社 | リポソームおよび薬物運搬体 |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| WO1996013590A2 (en) | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| NZ500216A (en) | 1997-04-16 | 2001-06-29 | American Home Prod | Beta-amyloid peptide-binding proteins and pharmaceutical use |
| JP4385152B2 (ja) | 1997-09-17 | 2009-12-16 | 三菱化学株式会社 | ２価反応性水溶性高分子誘導体及びそれを含有する複合体 |
| KR19990029749A (ko) | 1997-09-17 | 1999-04-26 | 미우라 아끼라 | 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체 |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| WO1999041279A2 (en) | 1998-02-13 | 1999-08-19 | Arch Development Corporation | Methods and compositions comprising the use of blocked b-amyloid peptide |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US6025160A (en) | 1998-07-22 | 2000-02-15 | Smithkline Beecham Corporation | Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU784568B2 (en) | 1999-09-03 | 2006-05-04 | Ramot At Tel-Aviv University Ltd | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| JP5095061B2 (ja) | 1999-12-22 | 2012-12-12 | ネクター セラピューティックス | ポリ（エチレングリコール）の１−ベンゾトリアゾリル炭酸エステルの調製のための方法 |
| US6521635B1 (en) | 2000-01-20 | 2003-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of MXR transport by acridine derivatives |
| JP5025871B2 (ja) | 2000-02-21 | 2012-09-12 | エイチ．リュンドベック エイ／エス | アミロイドの新規なダウン−レギュレート方法 |
| JP2002047298A (ja) | 2000-07-10 | 2002-02-12 | Academia Sinica | 新規抗がん剤伝達系 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| WO2002009748A1 (en) | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| DE60139788D1 (de) | 2000-09-06 | 2009-10-15 | Aventis Pharma Sa | Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1270592B1 (de) | 2001-06-12 | 2004-09-29 | Wiltfang, Jens | Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa |
| ES2279869T3 (es) | 2001-06-20 | 2007-09-01 | Ramot At Tel Aviv University Ltd. | Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes. |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US7060270B2 (en) | 2001-11-02 | 2006-06-13 | Diagenics International Corporation | Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins |
| US20030229013A1 (en) | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US20080233181A1 (en) | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| PL378571A1 (pl) | 2003-02-01 | 2006-05-02 | Neuralab Limited | Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß |
| US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| FR2857875A1 (fr) | 2003-07-25 | 2005-01-28 | Univ Reims Champagne Ardenne | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| PT2465533E (pt) | 2004-02-20 | 2015-06-24 | Ac Immune Sa | Processos e composições que têm estruturas supramoleculares |
| WO2006066003A2 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| JP5249043B2 (ja) | 2005-12-12 | 2013-07-31 | エーシー イミューン ソシエテ アノニム | 治療ワクチン |
| JP5419131B2 (ja) | 2005-12-12 | 2014-02-19 | エーシー イミューン ソシエテ アノニム | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 |
| WO2010053763A1 (en) | 2008-10-29 | 2010-05-14 | Academia Sinica | Tumor-targeting peptides and uses thereof |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція |
-
2011
- 2011-10-26 AR ARP110103959A patent/AR083561A1/es not_active Application Discontinuation
- 2011-10-26 JP JP2013535421A patent/JP6027011B2/ja active Active
- 2011-10-26 WO PCT/EP2011/068797 patent/WO2012055933A1/en not_active Ceased
- 2011-10-26 CA CA2813833A patent/CA2813833C/en active Active
- 2011-10-26 CN CN201180051932.3A patent/CN103189050B/zh active Active
- 2011-10-26 EP EP11775949.8A patent/EP2632434B1/en active Active
- 2011-10-26 US US13/881,502 patent/US9687447B2/en active Active
- 2011-10-26 AU AU2011322553A patent/AU2011322553B2/en active Active
- 2011-10-26 TW TW100139025A patent/TW201223561A/zh unknown
- 2011-10-26 KR KR1020137013183A patent/KR101854943B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503475A5 (enExample) | ||
| EP2632434B1 (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| US20230141153A1 (en) | Stabilized rsv f proteins and uses thereof | |
| AU2018269742B2 (en) | Nano-enabled immunotherapy in cancer | |
| TWI827557B (zh) | Ｔａｕ胜肽之組成物及其用途 | |
| Razazan et al. | Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model | |
| US20250319075A1 (en) | Phosphoserine containing compositions for immune tolerance induction | |
| Martin-Rapun et al. | Targeted nanoparticles for the treatment of Alzheimer's disease | |
| EP2603233A1 (en) | Vaccine engineering | |
| WO2018017443A1 (en) | Immunogenic compositions and methods relating thereto | |
| JP2009510133A5 (enExample) | ||
| JP6416838B2 (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| JP2022116265A (ja) | 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法 | |
| JP2006028030A (ja) | リポソーム封入物質がエンドソームから脱出可能なリポソーム | |
| US11701328B2 (en) | Phosphoserine containing compositions for immune tolerance induction | |
| CN111295200A (zh) | 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒 | |
| JP2015514123A (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| US20230381309A1 (en) | Methods of treating diffuse large b-cell lymphoma | |
| HK1185262B (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| HK1185262A (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| Liu et al. | Spleen-Targeted mRNA Delivery via Long-Chain PEGylated lipids at Low Molar Ratio Enhances Antitumor Immunity Against Melanoma | |
| Xu et al. | Modular Assembly of Lipid Nanoparticles for Targeted mRNA Therapeutics and Vaccines | |
| CN119604312A (zh) | 用于体内递送的脂质组合物 |